Navalign LLC Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

Navalign LLC increased its stake in Zoetis Inc. (NYSE:ZTS) by 4.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 4,888 shares of the company’s stock after acquiring an additional 208 shares during the period. Navalign LLC’s holdings in Zoetis were worth $965,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. BOS Asset Management LLC boosted its stake in Zoetis by 3.2% in the 2nd quarter. BOS Asset Management LLC now owns 1,684 shares of the company’s stock worth $290,000 after purchasing an additional 53 shares during the period. Enterprise Financial Services Corp raised its holdings in shares of Zoetis by 2.3% during the 1st quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock worth $407,000 after acquiring an additional 55 shares in the last quarter. CreativeOne Wealth LLC raised its holdings in shares of Zoetis by 0.4% during the 2nd quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company’s stock worth $2,210,000 after acquiring an additional 57 shares in the last quarter. MJP Associates Inc. ADV raised its holdings in shares of Zoetis by 4.8% during the 3rd quarter. MJP Associates Inc. ADV now owns 1,275 shares of the company’s stock worth $222,000 after acquiring an additional 58 shares in the last quarter. Finally, TFC Financial Management Inc. raised its holdings in Zoetis by 3.3% during the 3rd quarter. TFC Financial Management Inc. now owns 1,918 shares of the company’s stock valued at $334,000 after buying an additional 61 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on ZTS shares. The Goldman Sachs Group increased their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. BNP Paribas initiated coverage on Zoetis in a research report on Thursday, December 7th. They set an “outperform” rating and a $237.00 price objective on the stock. Barclays increased their price target on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. Finally, Piper Sandler raised their price objective on Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 20th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus price target of $224.33.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the completion of the sale, the executive vice president now directly owns 17,569 shares of the company’s stock, valued at approximately $3,363,233.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 2,209 shares of company stock valued at $408,453 in the last three months. 0.12% of the stock is currently owned by company insiders.

Zoetis Trading Up 0.4 %

NYSE:ZTS traded up $0.61 on Thursday, reaching $169.12. The company’s stock had a trading volume of 3,395,584 shares, compared to its average volume of 2,739,733. Zoetis Inc. has a 12-month low of $151.03 and a 12-month high of $201.92. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The firm has a market cap of $77.43 billion, a price-to-earnings ratio of 33.36, a price-to-earnings-growth ratio of 2.53 and a beta of 0.87. The stock has a 50 day moving average price of $185.92 and a 200 day moving average price of $182.24.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period in the previous year, the firm earned $1.15 earnings per share. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities analysts anticipate that Zoetis Inc. will post 5.8 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.02%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.